<Basic Data>

<Related Data>

<Basic Data>

(million yen)
2020/03 2021/03 2022/03 2023/03 2024/03
Net Sales 29,20627,73434,85133,45636,213
Operating Profit 3,8962,2484,4952,114433
Ordinary Profit 3,9813,0245,3953,0691,691
Profit Attributable to Owners of Parent -10,8394,2623,7332,2362,186
Total Assets 68,74669,91575,24475,62581,795
Net Assets 59,76763,60466,34067,21672,282
Capital Adequacy Ratio(%) 86.991.088.288.988.4
Rate of Return On Equity(%) -16.36.95.73.33.1
Basic Earnings Per Share(yen) -192.1575.5466.3240.4940.08
Net Assets Per Share(yen) 1,059.401,127.141,179.461,232.411,324.82

<Related Data>

(Millions of Yen)
2018/03 2019/03 2020/03 2021/03 2022/03
Net sales by segment
<Pharmaceuticals>(Millions of Yen)
25,503 21,068 22,729 20,793 25,696
Net sales by segment
<LAL>(Millions of Yen)
5,931 6,491 6,476 6,941 9,155
Overseas Sales
(Millions of Yen)
12,281 12,098 13,205 14,361 17,918
Overseas Sales Ratio
(to Net Sales)(excluding royalty income)
(%)
41.5 43.8 46.8 50.5 56.6
R&D Expenses
(Millions of Yen)
8,408 7,148 6,877 7,209 9,005
R&D Expenses Ratio
(to Net Sales)(excluding royalty income)
(%)
29.7 26.7 25.2 26.7 29.2
Amount of Capital Expenditure
(Millions of Yen)
1,591 1,310 2,109 2,127 2,194
Depreciation and Amortization
(Millions of Yen)
2,925 2,902 1,778 808 1,051

Related Information